![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, August 02, 2014 7:51:55 PM
It will only be important if the Lympro identifies people who will respond to p16.
That is, if p16 works in humans. We will find that out in about ten years.
IOW, given that the administration of p16 will be very expensive, if for some reason, Lympro identifies those who will do well, then there will be reason to give the test.
In that case, it would be like the apo e gene which identifies those who may get AD.
Once again, my dad went into assisted living just today with ad. He would not benefit from that test, nor would I or any of my siblings. I am sure.
As far as the fda rules are concerned, this test is not life altering nor is it for a rare disease.
As I said, I have enough to stuff into my head, but you just can't ignore this, this new FDA reg is good in general. Whether or not it pertains to Lympro remains to be seen.
You would think that nothing happened on Thursday, based on this board. It did happen, and it was relevant, and it was negative, again.
The truth is incontrovertible. Malice may attack it, ignorance may deride it, but in the end, there it is.
Winston Churchill
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM